STASYS
Stasys Medical Corporation develops the Atlas Platelet Strength Test, an investigational, benchtop, reagent-less diagnostic that measures platelet function and bleeding risk from whole blood in roughly 3-5 minutes for hospital trauma, emergency, surgical, and cardiology use.
- Company typePrivate
- Founded2013
- HeadquartersHuntersville, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What STASYS does
Stasys Medical Corporation (brand: Atlas Platelet Strength Test, or Atlas PST) is a privately held, research-stage medical device company founded in 2013 with operations in the Seattle, Washington area. The company develops a benchtop diagnostic system that measures platelet strength, aggregation, contraction, resistance, and likelihood of clot dissolution from a whole blood sample in roughly 3-5 minutes without the use of external reagents or agonists. The underlying technology combines proprietary microfluidic-micropost sensors - originally developed under a DARPA Young Faculty Award by co-founder Nate Sniadecki - with shear-based mechanical platelet activation, machine vision imaging, and machine learning algorithms to deliver a reagent-less, point-of-care assessment of primary hemostasis that incumbents (TEG/ROTEM, light-transmission aggregometry, PFA-100) do not provide.
The product is labeled 'Investigational Device Only; Not for Commercial Use' and has not been FDA-cleared, so today's activity is clinical research rather than commercial sale. Stasys is running multiple NIH-funded studies across trauma surgery, emergency medicine, cardiology (antiplatelet therapy monitoring), transfusion medicine (platelet quality for transfusion), and cardiothoracic/ECMO surgery, anchored by an NIH CATALYZE R33 grant (2022) supporting a 1,000-patient study at Vanderbilt University Medical Center. The commercial go-to-market, once cleared, is planned as direct enterprise sales of the benchtop analyzer into hospital trauma centers, emergency departments, and clinical laboratories, with a recurring consumables revenue stream from single-use disposable microfluidic cards (razor-and-blade mechanics). Headcount sits at 1-10 employees and disclosed funding totals approximately $2.1 million of equity led by Table10 Group in 2015, supplemented by NSF and NIH SBIR/CATALYZE grants; the company is currently soliciting additional investor capital via its website.
STASYS firmographics
Firmographics- Name
- STASYS
- Legal name
- Stasys Medical Corporation
- Website
- https://stasysmedical.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Stasys Medical Corporation develops the Atlas Platelet Strength Test, an investigational, benchtop, reagent-less diagnostic that measures platelet function and bleeding risk from whole blood in roughly 3-5 minutes for hospital trauma, emergency, surgical, and cardiology use.
- Ownership category
- akta.pro rank
STASYS industry classification
Industry- Product category
- Point-of-Care Platelet Function Diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE)
Keywords
Where STASYS is headquartered
LocationHeadquarters
- HQ city
- Huntersville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
STASYS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Medical Device System Sales: Sale of benchtop ATLAS platelet testing machine to hospitals and clinical facilities. The system consists of the machine, single-use disposable cards, and associated consumables.
- Single-use Disposable Cards: Recurring revenue from single-use microcards required for each test, creating a consumables revenue stream.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
STASYS product offering
Product offeringCore offering
STASYS (Stasys Medical Corporation) develops a benchtop point-of-care diagnostic system called the Atlas Platelet Strength Test (Atlas PST) that measures platelet strength, aggregation, contraction, and function in whole blood samples using shear force activation, microfluidics, machine vision, and machine learning. The system consists of a benchtop analyzer and single-use disposable microfluidic cards, delivering platelet function results in approximately 3 minutes without the need for external reagents or offsite laboratory engagement. The product is currently labeled 'Investigational Device Only; Not for Commercial Use' in the United States.
Product overview
STASYS offers a single unified diagnostic system called the Stasys Platelet System (also marketed as the Atlas Platelet Strength Test or Atlas PST). The system consists of three integrated components: The Machine (the benchtop analyzer), The Card (single-use microfluidic sensor card), and The Sensor (proprietary micron-scale sensor technology). The system uses shear force to mimic natural platelet activation without reagents, measuring platelet strength, aggregation, and function in under 5 minutes from a whole blood sample. The components work together as a complete point-of-care diagnostic solution for assessing primary hemostasis.
Differentiator
Problem solved
Functional benefit
Brands
- Atlas Platelet Strength Test (PST): A global assay of primary hemostasis, function, and aggregation in a reagent-less native blood sample. Measures platelet adhesion, activation, aggregation, and contraction.
Products and services
- Stasys Platelet System (Atlas Platelet Strength Test / Atlas PST)
Quantifiable outcome
- Test results in 3 minutes compared to 30-60 minutes for existing methods
- +4 more outcomes
Companies that use STASYS
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
STASYS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
STASYS partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Vanderbilt University Medical Center (VUMC)coreMulti-year collaboration for 1000-patient clinical study at VUMC Emergency Medical Center. Grant Title: NIH CATALYZE R33 grant. Focuses on using ATLAS outputs to predict bleeding, blood product transfusion requirements, and patient outcomes, as well as developing AI-powered models for improving detection of platelet dysfunction.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
STASYS competitors and assessment
Company assessmentDirect peers
- Haemonetics: Haemonetics manufactures the TEG (Thromboelastograph) platform, the most widely adopted viscoelastic hemostasis assessment system globally and the direct incumbent competitor to Stasys ATLAS in trauma, cardiac surgery, and ED platelet-function testing.
- Werfen (Tem Innovations / Instrumentation Laboratory): Werfen's ROTEM (rotational thromboelastometry) is the principal global competitor to TEG and a direct head-to-head alternative to Stasys for whole-blood hemostasis assessment in trauma and perioperative settings.
- Diagnostica Stago: Stago manufactures the STA line of hemostasis analyzers (including dedicated platelet-function assays) used in hospital hemostasis labs, competing for the same coagulation diagnostics budget as ATLAS and frequently displacing viscoelastic systems in central-lab-led workflows.
- Sienco (Sonoclot): Sienco's Sonoclot viscoelastic analyzer is a long-standing point-of-care hemostasis platform used in cardiac surgery and critical care, offering another direct alternative for platelet-function and clot-strength assessment at the bedside.
- Sekisui Diagnostics (formerly Sekisui America / American Diagnostica): Sekisui Diagnostics supplies specialized coagulation reagents,血小板功能 assays, and POC hemostasis platforms, directly competing with ATLAS in the reagent-driven platelet-function segment.
Broad incumbents
- Siemens Healthineers: Siemens offers the INNOVANCE and Sysmex CA-series coagulation analyzers as part of a broad central-lab diagnostics portfolio, representing the dominant non-viscoelastic incumbent for hospital hemostasis testing that could bundle or compete with ATLAS at procurement.
- Abbott (i-STAT): Abbott's i-STAT and POC diagnostics franchise dominates bedside blood testing in US EDs and ICUs, creating both a competitive overlap (POC diagnostics in trauma) and a potential channel partnership for ATLAS given the shared ED footprint.
- Hologic: Hologic's diagnostic division (formerly Gen-Probe) operates in women's health and hemostasis-adjacent specialty diagnostics; it represents the broader class of venture-backed diagnostics acquirers that routinely roll up novel platelet and coagulation assets.
- Sysmex: Sysmex is a global leader in hematology and coagulation diagnostics (CN-series and CA-series analyzers), competing with Stasys for hospital hemostasis budget and serving as a likely strategic acquirer given its scale and POC-coagulation roadmap.
- Beckman Coulter: Beckman Coulter (Danaher) supplies the DxH and ACL-series hematology and coagulation analyzers used in hospital labs; as a Danaher-owned diagnostics platform, it is the archetypal strategic-acquirer threat and channel alternative for trauma centers evaluating Stasys.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
STASYS social profiles
Digital presenceSTASYS compliance and trust
Trust signalCompliance1 record
STASYS financial estimates
Financial estimateRevenue estimate
Valuation estimate
STASYS leadership team
Management profileNumber of profiles
Profiles5 records
STASYS funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
STASYS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about STASYS
What does STASYS do?
STASYS (Stasys Medical Corporation) develops a benchtop point-of-care diagnostic system called the Atlas Platelet Strength Test (Atlas PST) that measures platelet strength, aggregation, contraction, and function in whole blood samples using shear force activation, microfluidics, machine vision, and machine learning. The system consists of a benchtop analyzer and single-use disposable microfluidic cards, delivering platelet function results in approximately 3 minutes without the need for external reagents or offsite laboratory engagement. The product is currently labeled 'Investigational Device Only; Not for Commercial Use' in the United States.
Is STASYS a public or private company?
STASYS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was STASYS founded?
STASYS was founded in 2013. It employs 1 to 10 people.
Where is STASYS based?
STASYS is headquartered in Huntersville, United States, in the North America region.
How does STASYS make money?
Two revenue lines are on record. Medical Device System Sales are the primary driver. The others are single-use Disposable Cards.
Who are STASYS's main competitors?
Direct peers on record are Haemonetics, Werfen (Tem Innovations / Instrumentation Laboratory), Diagnostica Stago, Sienco (Sonoclot) and Sekisui Diagnostics (formerly Sekisui America / American Diagnostica). Broad incumbents are Siemens Healthineers, Abbott (i-STAT), Hologic, Sysmex and Beckman Coulter.
Does STASYS have an API?
No public API is recorded for STASYS.
What industry is STASYS in?
STASYS's product category is Point-of-Care Platelet Function Diagnostics. Its primary akta.pro industry code is HLACANAE, SaMD – Monitoring, Triage & Risk Stratification Software. Its NAICS code is 334510 and its SIC code is 3841.